| Literature DB >> 30589612 |
Ashwini K Devkota1, John R Veloria1, Hou-Fu Guo2, Jonathan M Kurie2, Eun Jeong Cho1, Kevin N Dalby1,3.
Abstract
Lysyl hydroxylase-2 (LH2) catalyzes the hydroxylation of telopeptidyl lysine residues on collagen, leading to the formation of stable collagen cross-links that connect collagen molecules and stabilize the extracellular matrix. High levels of LH2 have been reported in the formation and stabilization of hydroxylysine aldehyde-derived collagen cross-links (HLCCs), leading to fibrosis and cancer metastasis in certain tissues. Identification of small-molecule inhibitors targeting LH2 activity requires a robust and suitable assay system, which is currently lacking. Thus, despite being a promising target for these diseases, small-molecule inhibitors for LH2 have yet to be reported. Therefore, we developed a luminescence-based strategy to monitor LH activity and validated its ability to identify new inhibitors in a screen of approximately 65,000 compounds against LH2. Primary hits were confirmed using the same LH assay against mimiviral L230. This newly developed LH assay is robust, suitable for high-throughput screening, and able to identify potent specific inhibitors of LH2.Entities:
Keywords: cancer; high-throughput screen; luminescence; lysyl hydroxylase-2 (LH2); succinate detection
Mesh:
Substances:
Year: 2018 PMID: 30589612 PMCID: PMC6535306 DOI: 10.1177/2472555218817057
Source DB: PubMed Journal: SLAS Discov ISSN: 2472-5552 Impact factor: 3.341